Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Carboxymethylcellulose Sodium; Glycerol; Hyaluronic Acid

Criteria

Inclusion Criteria:

• Have been using artificial tears for at least 3 months prior to study inclusion

• Have been using preservative free artificial tears at least three times daily (TIB) for at least 2 weeks immediately prior to study inclusion

• Having moderate to severe symptoms suggestive of dry eye

Exclusion Criteria:

• Current enrollment in an investigational drug or device study or participation in such a study within 3 months prior to entry into this study

• Moderate to severe blepharitis

• History or active signs of ocular trauma, ocular infection, or ocular inflammation within the last 3 months

• History or active signs of ocular allergic disease or ocular herpes within the last year

• History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time.